The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
Status:
Completed
Trial end date:
2015-05-14
Target enrollment:
Participant gender:
Summary
Specific Aim: To determine the effectiveness of Roflumilast in improving i) whole right lung
and ii) peripheral right lung mucociliary clearance (MCC) in patients with COPD and chronic
bronchitis.
Hypothesis: Roflumilast increases mucociliary clearance in patients with chronic bronchitis.
Study Design: This will be a double-blinded, cross-over randomized controlled trial with 1:1
randomization of 20 individuals with chronic bronchitis. Subjects will undergo baseline MCC
then will be randomized to either roflumilast or placebo x 4 weeks, then there will be a 4
week wash-out phase and a second 4 week period of roflumilast/placebo depending on initial
randomization. MCC will be conducted at baseline and at the end of each 4 week medication
phase.